Fig. 4: Karonudib treatment does not hamper T-cell-mediated anti-tumor immunity. | Cell Death & Disease

Fig. 4: Karonudib treatment does not hamper T-cell-mediated anti-tumor immunity.

From: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma

Fig. 4

a Quantitative analysis of the degranulation marker CD107 on TILs from patient sample M151002 grown with or without autologous tumor cells and with or without karonudib, data shown as average of triplicates (±SD). b Concentration of IFN-gamma in the media of the M15002 tumor cells cultured with or without autologous TILs and with or without karonudib. The ELISA data are shown as average of triplicates (±SD). c–e Size or luminescence signal of PDX tumors treated with vehicle (black), karonudib (red), injected with autologous TILs (blue) or karonudib + TILs (green), data are shown as average of four mice (±SEM). f B6 mice bearing tumors established from B16 mouse melanoma cell line, treated with either vehicle, CTLA4 antibody, karonudib, or combination of CTLA4 antibody and karonudib. Data in (f) shown as average tumor size of four mice (±SEM)

Back to article page